The decline in NextCure's stock price suggests that the updates provided were not in line with investor expectations. Clinical pipeline updates are critical for biotech companies as they directly relate to the company's future prospects and potential revenue streams. Negative market reaction can often follow if the updates are perceived as unsatisfactory or if they indicate delays or failures in drug development.